Keros Therapeutics
KROS • NASDAQ
Keros Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jasbir S. Seehra, with a market cap of $209.2M.
CEOJasbir S. Seehra
Next Earnings
Upcoming earnings announcement for Keros Therapeutics
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.96
Revenue Estimate
$2.6M
Earnings History
Past 12 earnings reports for Keros Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Q4 2025 | -$0.86Est: -$0.47 | -83.0% | $385.0KEst: $4.8M | -92.0% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.18Est: -$1.00 | +82.0% | $14.3MEst: $5.6M | +154.6% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.76Est: -$1.13 | +32.7% | $18.2MEst: $5.6M | +224.0% | 10-Q |
| May 6, 2025 | Q1 2025 | $3.62Est: $0.01 | +36100.0% | $211.2MEst: $56.7M | +272.9% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$1.14Est: -$0.96 | -18.7% | $3.0M | — | 10-K |
| Nov 6, 2024 | Q3 2024 | -$1.41Est: -$1.27 | -11.0% | $388.0K | — | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$1.25Est: -$1.23 | -1.6% | $37.0K | — | 10-Q |
| May 8, 2024 | Q1 2024 | -$1.21Est: -$1.34 | +9.7% | $83.0K | — | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$1.34Est: -$1.37 | +2.2% | $143.0K | — | 10-K |
| Nov 6, 2023 | Q3 2023 | -$1.33Est: -$1.35 | +1.5% | $8.0K | — | — |
| Aug 7, 2023 | Q2 2023 | -$1.27Est: -$1.34 | +5.2% | -Est: $220.0K | -100.0% | 10-Q |
| May 4, 2023 | Q1 2023 | -$1.26Est: -$1.12 | -12.5% | -Est: $220.0K | -100.0% | — |